Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ /HER2-) breast cancer is the most common subtype in females, frequently challenged by resistance to endocrine therapy and CDK4/6 inhibitors. Here we show that N-acetylneuraminate synthase (NANS) is significantly upregulated in female HR+ ...
Jia-Yang Cai, Minhua Huang, Shaoyou Yang et al.· Nature Communications· 0 citations
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al.· Journal of Hematology & Onco...· 0 citations
A role of ZNF689 is identified in regulation of homologous recombination repair via stabilization of the MRN complex, with ZNF689 deficiency conferring sensitivity to PARP inhibition, which upregulates PD-L1 expression and sensitizes tumors to combination therapy with anti-PD-L1 in TNBC.
